re: Ann: Productive Meeting With FDA Regardin... Agree Lopez
Looks like there's hopefully a good chance the additional data analysis post initial submission might be fine, just FDA caution. Which would indicate lower end of timeframe to be back on track and no doomsday scenario.
Add to My Watchlist
What is My Watchlist?